Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [11C]PE2I in healthy volunteers

Nuclear Medicine and Biology

Volumn 34, Issue 4, 2007, Pages 465-470

  Ribeiro, Maria João ^a   Ricard, Marcel ^b   Lièvre, Marie Angele ^a   Bourgeois, Sandrine ^a   Emond, Patrick ^c   Gervais, Philippe ^a   Dollé, Frédéric ^a   Syrota, André ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSERM   (France)

Author keywords

11C PE2I; DAT; Dosimetry; PET; Whole body distribution

Indexed keywords

DOPAMINE TRANSPORTER; N (3 IODOPROP 2 ENYL) 2BETA CARBOMETHOXY 3BETA (4' TOLYL)NORTROPANE C 11; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLADDER MUCOSA; BLOOD PRESSURE MEASUREMENT; BRAIN; DOPAMINERGIC TRANSMISSION; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG RETENTION; DRUG UPTAKE; ELECTROCARDIOGRAPHY MONITORING; HUMAN; HUMAN EXPERIMENT; KIDNEY; LIVER; MALE; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; RADIATION ABSORPTION; SALIVARY GLAND; STOMACH;

ADULT; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RADIOPHARMACEUTICALS; REFERENCE VALUES; TISSUE DISTRIBUTION;

EID: 34248171584     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.02.005     Document Type: Article

References (19)

1. 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease. J Nucl Med 44 (2003) 663-670
2. Asanuma K., Dhawan V., Carbon M., and Eidelberg D. Assessment of disease progression in parkinsonism. J Neurol 251 Suppl 7 (2004) vII4-vII8
3. Guilloteau D., Emond P., Baulieu J.L., Garreau L., Frangin Y., Pourcelot L., et al. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4′-methylpheny l)nortropane (PE2I). Nucl Med Biol 25 (1998) 331-337
4. 125I]PE2I. NeuroImage 9 (1999) 108-116
5. Emond P., Garreau L., Chalon S., Boazi M., Caillet M., Bricard J., et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4′-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3′,4′-dis ubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 40 (1997) 1366-1372
6. Chalon S., Garreau L., Emond P., Zimmer L., Vilar M.P., Besnard J.C., et al. Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4′-methylpheny l)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther 291 (1999) 648-654
7. Chalon S., Emond P., Bodard S., Vilar M.P., Thiercelin C., Besnard J.C., et al. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease. Synapse 31 (1999) 134-139
8. 18F]fluoro-l-dopa. J Cereb Blood Flow Metab 21 (2001) 782-792
9. 123I-PE2I SPECT. NeuroImage 19 (2003) 810-816
10. 11C]PE2I, a selective radioligand for the quantification of the dopamine transporter using PET. J Label Compounds Radiopharm 43 (2000) 997-1004
11. Watson C.C., Newport D., Casey M.E., et al. Evaluation of simulation-based scatter correction for 3D PET cardiac imaging. IEEE Trans Nucl Sci 44 (1997) 90-97
12. Comtat C., Kinahan P.E., Defrise M., and Townsend D.W. Fast reconstruction of 3D PET data with accurate statistical modeling. IEEE Trans Nucl Sci 45 (1998) 1083-1089
13. Loevinger R., Budinger T.F., and Watson E.E. MIRD Primer for absorbed dose calculations (1991), The Society of Nuclear Medicine, New York (NY)
14. Cristy M., and Eckerman K.F. Specific absorbed fractions of energy at various ages from internal photons sources. ORNL Report ORNL/TM-8381 V1-V7 (1987), Oak Ridge National Laboratory, Oak Ridge (Tenn)
15. Stabin M.G. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37 (1996) 538-546
16. ICRP Publication 60. Recommendations of the International Commission on Radiological Protection. Ann ICRP 21 (1991) 493-502
17. Kuikka J.T., Tupala E., Bergstrom K.A., Hiltunen J., and Tiihonene J. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects. Eur J Nucl Med 26 (1999) 1486-1488
18. Beekhuis H. Population radiation absorbed dose from nuclear medicine procedures in the Netherlands. Health Phys 54 (1988) 287-291
19. International Commission on Radiological Protection. ICRP Publication 62. Radiological protection in biomedical research. Ann ICRP 22 (1991) 1-28